Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

被引：0
作者：
Greenberg, Arthur [1 ]
机构：
[1] Duke Univ, Dept Med, Div Nephrol, Med Ctr, Durham, NC 27710 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 50卷 / 06期
关键词：
D O I：
10.1053/j.ajkd.2007.10.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：904 / 907
页数：4
相关论文
共 13 条
[1]   Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial [J].
Gheorghiade, M ;
Gattis, WA ;
O'Connor, CM ;
Adams, KF ;
Elkayam, U ;
Barbagelata, A ;
Ghali, JK ;
Benza, RL ;
McGrew, FA ;
Klapholz, M ;
Ouyang, J ;
Orlandi, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1963-1971
[2]   Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials [J].
Gheorghiade, Mihai ;
Konstam, Marvin A. ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Udelson, James E. ;
Zannad, Faiez ;
Cook, Thomas ;
Ouyang, John ;
Zimmer, Christopher ;
Orlandi, Cesare .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12) :1332-1343
[3]   Vasopressin receptor antagonists [J].
Greenberg, A. ;
Verbalis, J. G. .
KIDNEY INTERNATIONAL, 2006, 69 (12) :2124-2130
[4]   Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations [J].
Klein, L ;
O'Connor, CM ;
Gattis, WA ;
Zampino, M ;
de Luca, L ;
Vitarelli, A ;
Fedele, F ;
Gheorghiade, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (09) :18F-40F
[5]   Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial [J].
Konstam, Marvin A. ;
Gheorghiade, Mihai ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Udelson, James E. ;
Zannad, Faiez ;
Cook, Thomas ;
Ouyang, John ;
Zimmer, Christopher ;
Orlandi, Cesare .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12) :1319-1331
[6]   Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia [J].
Madias, Nicolaos E. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) :184-187
[7]   Short-term risk of death after treatment with nesiritide for decompensated heart failure - A pooled analysis of randomized controlled trials [J].
Sackner-Bernstein, JD ;
Kowalski, M ;
Fox, M ;
Aaronson, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (15) :1900-1905
[8]   Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J].
Sackner-Bernstein, JD ;
Skopicki, HA ;
Aaronson, KD .
CIRCULATION, 2005, 111 (12) :1487-1491
[9]   Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia [J].
Schrier, Robert W. ;
Gross, Peter ;
Gheorghiade, Mihai ;
Berl, Tomas ;
Verbalis, Joseph G. ;
Czerwiec, Frank S. ;
Orlandi, Cesare .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2099-2112
[10]   PATHOGENESIS OF SODIUM AND WATER-RETENTION IN HIGH-OUTPUT AND LOW-OUTPUT CARDIAC-FAILURE, NEPHROTIC SYNDROME, CIRRHOSIS, AND PREGNANCY .2. [J].
SCHRIER, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (17) :1127-1134
12